文献速递艾滋病与性传播感染

乌干达启动抗逆转录病毒治疗的成人HIV耐药调查

HIV drug resistance among adults initiating antiretroviral therapy in Uganda.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究采用WHO 2014年修订的HIV耐药监测策略,在乌干达23个站点以两阶段整群抽样调查≥18岁启动或重新启动ART的成人。491份样本中351份成功基因分型,49份存在耐药突变,加权HIVDR总患病率为18.2%,NNRTI类最高为14.1%。结论认为NNRTI耐药率超过WHO推荐的10%阈值,应转向含多替拉韦的一线方案。

要点

  • 乌干达启动或重新启动ART成人加权HIVDR总患病率为18.2%。
  • NNRTI耐药患病率最高,达14.1%,超过WHO推荐的10%换药阈值。
  • 含多替拉韦方案已被乌干达修订指南列为一线和二线首选。

核心结论

  • 乌干达启动或重新启动ART的成人中NNRTI耐药患病率高达14.1%,超过WHO推荐的10%阈值。
  • 该结果支持将一线方案从NNRTI为基础转向含多替拉韦的方案,且该推荐已被乌干达修订指南采纳。

研究设计与样本

  • 对象为≥18岁启动或重新启动ART的成人,共采集491份样本,351份成功基因分型。

主要发现

  • 491名参与者中位年龄32岁,女性占61.5%。
  • 351份成功基因分型样本中49份存在耐药突变,加权HIVDR总患病率为18.2%。
  • NNRTI类耐药患病率最高,为14.1%。

关键数值与推荐

  • WHO推荐当NNRTI耐药率超过10%阈值时,应考虑将一线方案从NNRTI为基础改为含多替拉韦方案。
  • 乌干达修订版ART指南已采纳该推荐,含多替拉韦方案为一线和二线首选。

临床怎么用

  • 在NNRTI耐药率超过10%的地区,启动或重新启动ART时应优先选用含多替拉韦的方案。
  • 国家ART方案制定可参考本调查方法获得的全国代表性HIVDR患病率数据。

局限性

  • 491份样本中仅351份成功基因分型,存在未分型样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: WHO revised their HIV drug resistance (HIVDR) monitoring strategy in 2014, enabling countries to generate nationally representative HIVDR prevalence estimates from surveys conducted using this methodology. In 2016, we adopted this strategy in Uganda and conducted an HIVDR survey among adults initiating or reinitiating ART. METHODS: A cross-sectional survey of adults aged ≥18 years initiating or reinitiating ART was conducted at 23 sites using a two-stage cluster design sampling method. Participants provided written informed consent prior to enrolment. Whole blood collected in EDTA vacutainer tubes was used for preparation of dried blood spot (DBS) specimens or plasma. Samples were shipped from the sites to the Central Public Health Laboratory (CPHL) for temporary storage before transfer to the Uganda Virus Research Institute (UVRI) for genotyping. Prevalence of HIVDR among adults initiating or reinitiating ART was determined. RESULTS: Specimens from 491 participants (median age 32 years and 61.5% female) were collected between August and December 2016. Specimens from 351 participants were successfully genotyped. Forty-nine had drug resistance mutations, yielding an overall weighted HIVDR prevalence of 18.2% with the highest noted for NNRTIs at 14.1%. CONCLUSIONS: We observed a high HIVDR prevalence for NNRTIs among adults prior to initiating or reinitiating ART in Uganda. This is above WHO's recommended threshold of 10% when countries should consider changing from NNRTI- to dolutegravir-based first-line regimens. This recommendation was adopted in the revised Ugandan ART guidelines. Dolutegravir-containing ART regimens are preferred for first- and second-line ART regimens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Watera C, Ssemwanga D, Namayanja G, et al. HIV drug resistance among adults initiating antiretroviral therapy in Uganda. J Antimicrob Chemother. 2021. PMID: 33993252. doi:10.1093/jac/dkab159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。